X
Supply constraint of Creon® (Pancreatin) Micro, 10,000 and 25,000
July 2026
Based on the latest information provided by Abbott, our third-party manufacturing partner, the manufacturing facility expansion timeline has been updated. The API expansion is expected to be ready in time to deliver finished product to market by Q2 2027, with supply expected to increase progressively thereafter.
This constrained supply is due to high global demand and reaching maximum manufacturing supply output.
Viatris is currently in stock of all marketed strengths of Creon® and is receiving a continuous supply of Creon® from Abbott. Distribution of all marketed strengths of Creon® from Abbott will continue to be regularly distributed to our wholesale partners and onwards to pharmacies in the UK as shipments arrive.
We are committed to providing reliable access to medicines for our patients and fully appreciate how important this medicine is for individuals who rely on pancreatic enzyme replacement therapy (PERT) and understand the challenges this situation poses for patients and their healthcare professionals.
It is recommended that patients affected should speak to their treating physician to discuss treatment options, according to their health needs and their relevant clinical history. Viatris is in regular contact with the Department of Health and Social Care, patient association groups and healthcare professionals to provide frequent updates on the supply status.
The Creon® customer service line continues to be available and can be reached via 0800 8086410. Operators will respond from the UK and handle enquiries in real time. The service will be active from Monday to Friday from 9:00 to 17:00.
If you require additional information or have any questions, please contact Customer Services on 01707 853100 or via email at productenquiries@viatris.co.uk. For medical enquiries, please contact our Medical Information team on 01707 853000 or via email at info.uk@viatris.com .
UK-CRE-2026-00025 August 2026